Evidence construction of Chinese herbal formulae for the treatment of H. pylori positive peptic ulcer: A Bayesian network Meta-analysis

Yang, Jiayue; Yang, Heng; Dai, Yao; Jiang, Yinxiao; Long, Yuhao; Zeng, Jinhao; Ma, Xiao

doi:10.1016/j.phymed.2022.154327

Cited by 1 publication

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, JWYY+T/Q might be deemed the most advantageous choice, followed by KFX+T/Q. An NMA66 of Chinese herbal formulae for HP -positive PUD showed that the combination therapies involving TCMs held clinical significance. These Chinese herbal formulas included three CPMs such as JHWK, KFX and WFC.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of seven Chinese patent medicines combined with conventional triple/quadruple therapy forHelicobacter pylori-positive peptic ulcers: a systematic review and network meta-analysis

Jiang,

Deng,

Zhang

et al. 2024

BMJ Open

View full text Add to dashboard Cite

ObjectivesTo compare the efficacy and safety of seven Chinese patent medicines (CPMs) combined with conventional triple/quadruple therapy (T/Q) forHelicobacter pylori-positive peptic ulcers.DesignA systematic review and network meta-analysis.Data sourcesChina National Knowledge Infrastructure, VIP database, Wanfang database, ScienceDirect, EBSCO, EMBASE, Web of Science, Cochrane Library and PubMed were searched through 1 June 2022.Eligibility criteriaRandomised controlled trials (RCTs) testing CPMs combined with T/Q forH. pylori-positive peptic ulcers were included. The CPMs included Anweiyang capsule, Jianweiyuyang tablets/capsule/granule, Jinghuaweikang capsule, Kangfuxin liquid, Puyuanhewei capsule, Weifuchun tablets/capsule and Weisu granule. At least one of the following outcome indicators was recorded: complete ulcer healing rate (CUHR), effective rate (ER),H. pylorieradication rate (HPER), rate of peptic ulcer recurrence (RPUR) and incidence of adverse reactions (IAR).Data extraction and synthesisTwo researchers independently conducted the study selection and extracted data for included studies. The risk of bias was assessed using the Cochrane risk of bias tool. A pairwise meta-analysis was performed using RevMan V.5.3. Network meta-analysis was performed using STATA/MP V.15.0. Confidence in the evidence was assessed using Grading of Recommendations, Assessment, Development and Evaluation.ResultsA total of 36 RCTs involving 3620 patients were included. Compared with T/Q alone, Weisu+T/Q, Weifuchun+T/Q and Puyuanhewei+T/Q had the highest CUHR, ER andHPER, respectively. Weisu+T/Q and Jianweiyuyang+T/Q had the lowest RPUR and IAR, respectively. The cluster analysis results showed Jianweiyuyang+T/Q might be the best choice concerning efficacy and safety simultaneously, followed by Kangfuxin+T/Q.ConclusionAmong the combination therapies with the CPMs, Jianweiyuyang+T/Q might be the most favourable option forH. pylori-positive peptic ulcers, followed by Kangfuxin+T/Q. Considering the limited quantity and quality of the included RCTs, the results should be interpreted with caution.PROSPERO registration numberCRD42022327687.

show abstract

Section: Discussionmentioning

confidence: 99%